Clinical Trial: Prospective, Randomized, Sham-controlled, Dose-finding I/II Trial of Safety and Efficacy of Modified Optogenetic Gene Therapy (ZM-02 Injection)

U.S., Dec. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07282457) titled 'Prospective, Randomized, Sham-controlled, Dose-finding I/II Trial of Safety and Efficacy of Modified Optogenetic Gene Therapy (ZM-02 Injection)' on Nov. 26.

Brief Summary: This is a Phase 1/2, multi-center, randomized, sham-controlled, dose-escalation study evaluating ZM-02 in patients with advanced retinitis pigmentosa (RP).

Study Start Date: Feb. 25, 2026

Study Type: INTERVENTIONAL

Condition: Retinitis Pigmentosa (RP)

Intervention: GENETIC: ZM-02 (low dose)

Single unilateral IVT injection of low-dose ZM-02 in the study eye

GENETIC: ZM-02 (high dose)

Single unilateral IVT injection of high-dose ZM-02 in the study eye

GENE...